Skip to main content
梓橦宫 logo

梓橦宫 — Investor Relations & Filings

Ticker · 920566 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 625 across all filing types
Latest filing 2025-04-27 Audit Report / Informat…
Country CN China
Listing Beijing Stock Exchange 920566

About 梓橦宫

http://www.zitonggong.com/

Zitonggong specializes in the research, development, and production of specialized therapeutic agents. Established with a heritage dating back to 1780, the company holds a recognized heritage brand designation. Its primary product portfolio centers on neurological and cerebrovascular health, featuring Oxiracetam in various dosage forms for treating cognitive dysfunction and brain injuries. The company also develops treatments for digestive health, including Compound Aloe Capsules, and produces artificial Oriental Bezoar. Operations are centered on integrating traditional medicinal knowledge with modern chemical synthesis and manufacturing standards. The company maintains a focus on clinical efficacy and technological advancement in the fields of neurology and gastroenterology.

Recent filings

Filing Released Lang Actions
中汇会计师事务所（特殊普通合伙）关于四川梓橦宫药业股份有限公司非经营性资金占用及其他关联资金往来情况的专项审核说明
Audit Report / Information Classification · 95% confidence The document is titled as a "专项审核说明" which translates to a "special audit explanation" or "special review report" regarding non-operating fund occupation and other related party fund transactions for Sichuan Zitonggong Pharmaceutical Co., Ltd. It references an audit report number and states that it is a special audit opinion based on the 2024 annual financial statements audit. The document includes detailed audit responsibilities, management responsibilities, and a summary table of the related party fund transactions. It is a standalone audit report focusing on a specific aspect (non-operating fund occupation and related party transactions) rather than a full annual report or interim report. It is not a general announcement or a certification letter but a detailed audit opinion document. Therefore, it fits the category of Audit Report / Information (AR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement.
2025-04-27 Chinese
平安证券股份有限公司关于四川梓橦宫药业股份有限公司2024年度募集资金存放和使用情况的专项核查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项核查报告" (special inspection report) on the storage and use of raised funds for the year 2024 by Sichuan Zitonggong Pharmaceutical Co., Ltd., prepared by Ping An Securities Co., Ltd. It details the amount of funds raised, their storage, usage, investment projects, changes in investment projects, and compliance with relevant regulations. It includes detailed financial figures and tables about the raised funds and their management. The document also contains an auditor's verification opinion and the sponsor's inspection opinion on the raised funds usage. This type of report is a specialized audit or verification report focusing on the use of raised capital, not a full annual report or interim financial report. It is not an announcement or a brief summary but a detailed standalone audit-related report. Therefore, it fits the category of Audit Report / Information (AR). The document length (7587 characters) and content confirm it is a full report, not just an announcement or certification letter. FY 2024
2025-04-27 Chinese
2025年一季度报告
Interim / Quarterly Report Classification · 95% confidence The document is titled "2025 年第一季度报告" which translates to "2025 First Quarter Report." It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the period January to March 2025. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It is unaudited but contains substantive financial data and management commentary on financial results and business conditions for the quarter. This matches the definition of an Interim / Quarterly Report (IR). The document length is substantial (15,000 characters), and it is not merely an announcement or certification. Therefore, the correct classification is IR with high confidence. Q1 2025
2025-04-27 Chinese
2024年度独立董事述职报告（程志鹏）
Board/Management Information Classification · 95% confidence The document is titled as the "2024年度独立董事述职报告" which translates to "2024 Annual Independent Director's Work Report." It details the independent director's attendance at board and shareholder meetings, participation in committees, communication with audit institutions, and efforts to protect minority shareholders' rights. The content focuses on governance, oversight, and director duties rather than financial results or audit opinions. It is a detailed report on board/management activities and director responsibilities rather than a financial report or announcement. Therefore, it fits best under Board/Management Information (MANG). The document length is 2724 characters, which is relatively short but contains substantive content about management and board activities, not just an announcement or certification. Hence, it is not RPA or RNS.
2025-04-27 Chinese
关于2023年股权激励计划限制性股票首次授予部分第一个解除限售期解除限售条件成就的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Sichuan Zitonggong Pharmaceutical Co., Ltd. regarding the achievement of the first unlocking period conditions for the initial grant of the 2023 equity incentive plan. It details the number of shares to be unlocked, the involved personnel, the decision-making process, and legal opinions. The content focuses on the status and conditions of stock incentive plan unlocking, which is a capital/financing related update rather than a full financial report or earnings release. It is not a report publication announcement since it contains substantive information about the equity incentive plan and its unlocking conditions. Therefore, the document fits best under the category of Capital/Financing Update (CAP). The document length (7809 characters) and detailed content support this classification with high confidence.
2025-04-27 Chinese
内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制自我评价报告" which translates to "Internal Control Self-Evaluation Report." It is issued by the company's board and discusses the company's internal control system, its effectiveness, risk management, governance structure, and compliance with relevant laws and regulations. The document includes detailed descriptions of internal control policies, risk assessments, and the absence of significant deficiencies. It is dated April 28, 2025, and covers the period ending December 31, 2024. The content is comprehensive and focused on internal control evaluation rather than financial statements or audit opinions alone. This type of report is typically classified as an Audit Report / Information (AR) because it deals with internal control evaluations and compliance, which are part of audit-related disclosures but not the full annual report or standalone financial statements. The document is over 10,000 characters, indicating it is a full report rather than a brief announcement or certification. Therefore, the most appropriate classification is AR (Audit Report / Information). FY 2024
2025-04-27 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.